Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicentre, Phase II Study of TVD as Treatment for Children With Stage 4 Neuroblastoma Failing to Respond to First-Line Treatment According to HR-NBL-01/ E-SIOP [Topotecan-Vincristine-Doxorubicin in Children With Stage 4 Neuroblastoma Failing to Respond to COJEC (TVD)]

NCT00392340 is registered in ClinicalTrials.gov with Children's Cancer and Leukaemia Group as lead sponsor.

NCT NCT00392340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00392340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicentre, Phase II Study of TVD as Treatment for Children With Stage 4 Neuroblastoma Failing to Respond to First-Line Treatment According to HR-NBL-01/ E-SIOP [Topotecan-Vincristine-Doxorubicin in Children With Stage 4 Neuroblastoma Failing to Respond to COJEC (TVD)]
Lead sponsor
Children's Cancer and Leukaemia Group
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2008
Completion date
Not reported
Enrollment
63 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma